Project Grant R01HL171159
Award Date
7/15/24
Completion Date
6/30/28
Dollars Obligated
$775K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $242,310 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the Cardiovascular Diseases Research program (CFDA 93.837). This grant, titled "ADAPTING CELL-BASED THERAPIES FOR THE TREATMENT OF PULMONARY FIBROSIS", will support research focused on developing innovative cell-based therapies for the treatment of pulmonary fibrosis, a...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $695,403 award supports research to develop novel therapeutic approaches for treating pulmonary fibrosis by targeting dysfunctions in pulmonary endothelial cells. The central hypothesis is that restoring microvasculature integrity through nanoparticle gene therapy or cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $134,123 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) to investigate the biology of pulmonary fibrosis in pediatric hematopoietic cell transplant (HCT) patients. The goal is to enhance the ability to identify and treat pediatric HCT patients with or at risk for pulmonary fibrosis. UCSF will leverage bronchoalveolar lavage fluid and...
This $651,019 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research to elucidate the mechanisms driving dysfunctional epithelial repair in pulmonary fibrosis. The grant recipient, the Regents of the University of Michigan, will conduct studies to identify factors that induce aberrant epithelial cell states contributing to impaired alveolar regeneration, determine the role of...
This $5,715,866 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop a comprehensive understanding of the early pathogenesis and natural history of pulmonary fibrosis (PF). The primary awardee, the Regents of the University of Michigan, will lead 4 integrated research projects and 3 core facilities to investigate the transcriptomic, genetic, epigenetic, metabolic, and environmental factors that contribute to the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $153,130 to the University of California, San Diego (UCSD) to conduct research on identifying the cellular origins, molecular drivers, and biological roles of a novel population of fibroblasts in the lung periphery that may drive the progression of pulmonary fibrosis. The award aims to elucidate how these fibroblasts, characterized by...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to advance a novel gene therapy approach as a potential first-in-class treatment for idiopathic pulmonary fibrosis (IPF). The primary product to be developed and validated under this $1,193,262 award is an adeno-associated virus (AAV)-mediated gene therapy that targets the SGPL1 gene, which encodes an enzyme that regulates the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $464,121 to The Medical University of South Carolina (MUSC) from August 2024 to June 2026. The funding supports research to develop peptide-based therapies for the treatment of pulmonary fibrosis, a serious and fatal lung disease. Specifically, the project aims to simultaneously test identified anti-fibrotic peptides in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,061,189.00 in funding to the Regents of the University of Michigan to conduct research focused on immune crosstalk in lung injury and fibrosis. The key objectives are to study epithelial regulation of fibrosis and myeloid cell interactions, uncover mechanisms for impaired innate immunity against gram-positive infections in fibrosis,...
This federal Project Grant award in the amount of $542,402.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award supports a research project that aims to identify small molecules capable of reversing profibrotic gene signatures associated with idiopathic pulmonary fibrosis (IPF), a debilitating lung disease with high mortality. The key objectives are: 1) in silico discovery of drug candidates that...